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Abstract: Programmed cell death and especially apoptotic cell death, occurs under 
physiological conditions and is also desirable under pathological circumstances. However, 
the more we learn about cellular signaling cascades, the less plausible it becomes to find 
restricted and well-limited signaling pathways. In this context, an extensive description of 
pathway-connections is necessary in order to point out the main regulatory molecules as 
well as to select the most appropriate therapeutic targets. On the other hand, irregularities 
in programmed cell death pathways often lead to tumor development and cancer-related 
mortality is projected to continue increasing despite the effort to develop more active and 
selective antitumoral compounds. In fact, tumor cell plasticity represents a major challenge 
in chemotherapy and improvement on anticancer therapies seems to rely on appropriate 
drug combinations. An overview of the current status regarding apoptotic pathways as well 
as available chemotherapeutic compounds provides a new perspective of possible future 
anticancer strategies. 
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1. Introduction 
Cell death tends to occur in a regulated fashion under both physiological and pathological 
conditions. Apoptosis, historically termed necrobiosis or chromatolysis [1] and long used as a 
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synonym for programmed cell death, is an area of continuously expanding study. The more we know 
about organelle cross-talk and regulation, the less valid simple classifications become. Pure and 
watertight cell death pathways are no longer useful. Surface cell-death receptors and mitochondria 
have been classically considered to be key locations for the induction of apoptosis. Nevertheless, 
recent studies have revealed new regulated pathways that highlight the importance of other organelles 
in the modulation of apoptosis.  
Interest regarding the apoptotic process, and cell death pathways in general is strongly supported by 
the urgent need for efficient tumor cell death-inducing agents. According to the World Health 
Organization (WHO), cancer caused approximately 13% of the total deaths worldwide in 2007, and 
cancer-related mortality is projected to continue increasing (http://www.who.int/cancer/en/). In general 
terms, cancer (defined by the WHO as the uncontrolled growth and spread of cells) is treated by 
antiproliferative and/or cell death-inducing drugs. A better characterization of cell death/survival 
pathways and a more detailed description of the most commonly altered molecules in cancer has 
allowed the development of molecule-targeted drugs that aim to achieve more efficient anticancer 
strategies. Imatinib, a tyrosine kinase inhibitor [2], is considered to be the pioneer member of a rapidly 
expanding field that we will review here.  
2. Apoptosis: An Historical View 
The term apoptosis was coined by Kerr et al. [3] in 1972, but the concept is much older [4]. In 
1860, R. Virchow described a process for “physiological” cell degeneration and tissue degradation 
distinct from necrosis; he named it necrobiosis. Some years later, in 1885, W. Flemming coined the 
term chromatolysis (from Greek khroma = color, + lysis from lyein = to split) due to the fact that the 
broken up nucleus ultimately disappeared [1]. Notably, Flemming described this event as a 
spontaneous cell death and framed it among physiological processes. 
By 1972, a continuous loss of cells was assumed to take place in normal tissues in order to balance 
mitotic cell proliferation. Kerr et al. [3] mentioned that, unlike coagulative necrosis, the process they 
described was induced not just by noxious agents, but could also be detected under several 
physiological and pathological conditions. Moreover, they described a distinct mode of cellular death 
with ultrastructural features that were consistent with an active, inherently controlled phenomenon [3]. 
Despite the fact that the studies were based on ultrastructural analysis, Kerr et al. included two 
concepts that would be coined later: (1) apoptosis is an active process, i.e., ATP-dependent, and  
(2) apoptosis has been known as programmed cell death, an inherently controlled phenomenon. Some 
of the typical examples of apoptosis, such as apoptosis-mediated involution of phylogenetic vestiges in 
the embryo or its implication during normal organ and digit development, are from the 1970s. 
“Programmed cell death” has been used as a synonym for apoptosis to distinguish it from the other 
primary cell death process: necrosis. Recent data support the idea of an organized process behind 
necrotic cell death [5-7]. Therefore, programmed cell death is no longer proper terminology and the 
use of terms such as apoptosis, necrosis, or autophagic cell death is encouraged. 
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3. Morphological Characteristics of Apoptotic Cell Death 
Pioneer studies of apoptosis were based on camera lucida drawings, and later on electron 
microscopy and ultrastructural characterization. In 1972, another important concept was named: 
apoptotic bodies. Kerr et al. [3] suggested defining apoptotic bodies as “small, roughly spherical or 
ovoid cytoplasmic fragments, some of which contain pyknotic remnants of nuclei”. The apoptotic 
process was also divided into two discrete stages: (1) apoptotic body formation and (2) apoptotic body 
phagocytosis and degradation by other cells. General morphological features are currently the same as 
the ones described in that work. Table 1 contains a detailed list of primary morphological 
characteristics also illustrated in Figure 1 (for a review see [8]). 
Table 1. Main morphological and biochemical markers of apoptosis. Column on the left 
represents main morphological changes during the apoptotic process; column on the right 
summarizes main biochemical markers of the apoptotic cell death. 
Morphological Characterization Biochemical Characterization 
 
 
 
Apoptosis 
 Rounding-up  
(on attached cells) 
 Chromatine 
condensation 
 Reduction 
nuclear volumen 
(pyknosis) 
 
 Phosphatidylserine (PS) exposure 
 
 Activation of proapoptotic Bcl-2 
family proteins (e.g. Bax, Bak, Bid) 
 
 Increase of reactive oxygen specie 
(ROS) production 
 
 Activation of caspases 
 
 Dissipation of Δm 
 
 Mitochondrial membrane 
permeabilization 
 
 Oligonucleosomal DNA 
fragmentation 
 
 Plasma 
membrane blebbing 
 Nuclear 
fragmentation 
(karyorrhexis) 
Late apoptosis 
 Apoptotic body 
formation 
 Engulfment by 
phagocytes  
(in vivo) 
 Secondary 
necrosis (in vitro) 
4. Biochemical Characteristics of Apoptotic Cell Death 
Phosphatidylserine exposure in the outer leaflet of the plasma membrane is one, if not the unique, 
common feature of apoptotic cells, though phosphatidylserine exposure may also be present in 
processes other than cell death [8]. Phosphotidylserine is a phospholipid that, under general conditions, 
is “sequestered” in the inner leaflet of the plasma membrane by an ATP-dependent translocase. 
Elevation of the cytosolic Ca2+ concentration, which is common but not specific to the apoptotic 
process, has been shown to inhibit translocase activity and activate a scramblase (i.e., non-specific, 
bidirectional lipid flippase), leading to randomized phospholipid distribution in the plasma membrane [9]. 
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Moreover, phosphotidylserine translocation to the outer leaflet has been shown to occur in a cytosolic 
Ca2+-dependent and cytochrome c release-, caspase activation-, or DNA fragmentation-independent 
fashion [10], supporting previous data about apoptosis-independent phosphotidylserine exposure [9]. 
Figure 1. Apoptotic features by electron microscopy. Electronic micrographs of human  
T-cell acute lymphoblastic leukemia CCRF-CEM cells (5000x). Untreated CCRF-CEM 
cells (a) are characterized by a large nucleus, few cytoplasm and lack of obvious vacuoles. 
Apoptosis was induced by 4-HPR (3 µM) treatment. Cells undergoing apoptotic cell death 
(b-c) are distinguished by increased vacuolization of the cytoplasm and marginalization of 
the condensed chromatin (b) followed by micronuclei formation (c). 
 
 
During the apoptotic process, phosphotidylserine exposure in the outer leaflet has been suggested to 
activate macrophage-mediated phagocytosis [11], driving an inflammation-free cell clearance 
(secondary necrosis in the case of phagocyte-lacking in vitro systems, Table 1). The fact that 
phosphotidylserine-binding molecules, such as annexin V, can inhibit apoptotic cell clearance supports 
the role of phosphotidylserine in macrophage activation [9]. Nevertheless, the precise mechanism for 
apoptotic cell-macrophage/phagocyte interaction remains unclear. T-cell immunoglobulin mucin 
(TIM) family members, especially TIM-4, were recently proposed as phosphotidylserine-recognizing 
phagocyte receptors (as commented on by Savill and Gregory [12]), but the study of this process still 
has a long way to go.  
Regardless of common phosphotidylserine externalization and the morphological similarities, 
several subtypes of apoptosis have been described based on activated biochemical routes. According to 
the most general scheme, apoptotic processes can be divided into two major groups: extrinsic (or cell 
surface death-receptor mediated) and intrinsic (or receptor-independent) (Figure 2). The classification 
of other programmed cell death types, such as perforin/granzyme-mediated pathways (specific for T 
cells and natural killer cells), is not still clear [13,14].  
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Figure 2. General view of the primary apoptotic pathways in the cell. Death receptor-
dependent and –independent signaling pathways as well as signaling connections among 
different organelles are represented. Inhibitory effects are designed by while activation is 
designed by solid lined-arrows (    ). Dash lines (---) have been used to represent movement 
and interrogation marks (?) for proposed undetermined steps. 
 
 
4.1. Cell Death Receptor-mediated Apoptotic Pathway 
In the extrinsic pathway, the apoptotic signal is triggered by a ligand binding the corresponding cell 
surface receptor, followed by formation of the death inducing signaling complex (DISC) (Figure 2). 
The surface transmembrane receptors belong to the tumor necrosis factor receptor (TNFR) gene 
superfamily and share similar cysteine-rich extracellular domains and a cytoplasmic domain of about 
80 amino acids called the death domain (DD) [15]. 
Based on current data, there are three well characterized surface transmembrane receptor systems 
that ultimately form DISC: TNFR1 (activated upon TNF binding), CD95/Fas/Apo1 (activated by Fas 
ligand (FasL)), and death receptor 4 and 5 (DR4/5; activated by Apo2 ligand (Apo2L), also known as 
TRAIL or TNF-related apoptosis inducing ligand) [13].  
According to the current scenario, death receptors assemble prior to binding their corresponding 
ligands (TNF, FasL, or TRAIL). Upon receptor-ligand binding, receptors undergo a conformational 
change that is required for further adaptor protein recruitment (e.g., Fas-associated protein with DD 
(FADD), TNFR-associated protein with DD (TRADD)). Receptor-adaptor interaction occurs through 
the DD present in both groups. Adaptor proteins contain not just a DD, but also a death effector 
domain (DED), which is necessary for the recruitment and activation of cell death effectors, such as 
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initiator caspases (caspase-8 and -10) and the long form of cellular FLICE/caspase-8-like inhibitory 
protein (cFLIPL). The assembled cell death receptor-ligand-adaptor-effector complex forms the DISC 
(Figure 2) [13,16]. Among receptor binding proteins, receptor interacting protein 1 (RIP1) is a 
serine/threonine kinase with a DD domain that seems to be in the crossroads of several pathways and 
involved in main cellular processes, from proliferation to apoptosis and necrosis. RIP1 has been shown 
to bind to several death receptors, as well as to DD-containing adaptors like FADD and TRADD, 
through its own DD domain [17]. According to O’Donnell et al. [18], the ubiquitination status of RIP1 
could determine its function, switching from a pro-survival molecule in the receptor-bound, 
polyubiquitinated form to a pro-apoptotic, caspase-8-activating molecule when de-ubiquitinated. 
Therefore, ligand-mediated death receptor activation does not necessarily result in apoptosis induction. 
In regards to the receptor-mediated apoptosis induction scheme, the mechanism for initiator 
caspase activation is still being debated. Mammalian initiator caspases, together with effector 
caspases form a family of 11 cysteine-dependent aspartate-directed proteases synthesized as inactive 
zymogens. Activation of the zymogens requires the removal of a prodomain present in all caspases as 
well as the cleavage at the intersubunit linkers into the large (p20) and small (p10) subunits (for a 
comprenhensive review of caspases in apoptosis as well as other processes, read [19]). Caspases are 
currently considered to be the prime mediators of the apoptotic program execution although the 
relevance of other proteases is also increasing [20]. 
Back to the mechanisms involved in initiator caspase activation, Guicciardi and Gores [16] 
described the main hypothesis, referred to as “the induced-proximity model”, “proximity-induced 
dimerization model” (no cleavage required), and “conformational change-mediated activation model”. 
Regardless of the mechanism of activation, once activated the enzyme is released into the cytosol in an 
active heterotetrameric form that triggers a proteolytic cascade. Two downstream pathways are the 
most likely: (1) direct activation of effector caspases (e.g., caspase-3, -6, and -7), or (2) cleavage of the 
pro-apoptotic BH3-only protein Bid, which would further activate the mitochondrial apoptotic 
pathway (Figure 2). Current data suggest that downstream pathway-selection may be linked to the 
amount of active initiator caspase (e.g., active caspase-8) [16]. 
4.2. Cell Death Receptor-independent Apoptotic Pathways 
Cell death receptor-independent apoptotic pathways, also known as intrinsic apoptosis pathways, 
are initiated by a diverse set of non-receptor-mediated stimuli that act directly on targets within the 
cell. Signals that drive the intrinsic apoptosis pathway can be triggered by the absence of certain 
growth factors, hormones, or cytokines; the presence of negative environmental conditions  
(e.g., hyperthermia, hypoxia) or damaging agents, such as radiation, free radicals, and drugs; or viral 
infections [14].  
The intrinsic apoptotic pathway has been linked to mitochondrial damage and termed the 
mitochondrial apoptotic pathway [21,22]. However, more and more evidence indicates the 
involvement of other organelles, including the endoplasmic reticulum (ER), nucleus, or lysosomes as 
intrinsic apoptotic pathway checkpoints [13,23,24].  
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4.2.1. Mitochondria-triggered Intrinsic Apoptosis Pathway  
Mitochondria are the main “energy factories” in aerobic systems and, therefore, essential for 
cellular survival. Mitochondrial membrane potential (∆m) dissipation and mitochondrial membrane 
permeabilization (MMP) are considered two of the main events in the so-called “point-of-no-return” 
for cellular, but not necessarily apoptotic, death [8].  
Mitochondria are complex organelles with two main and unique characteristics: (1) the presence of 
its own genetic material (circular DNA) that encodes several, although not all, proteins of the 
mitochondrial respiratory chain and (2) a double membrane structure. The double membrane structure 
is essential for proton (H+) gradient formation, which ultimately drives energy generation (adenosine-
triphosphate, ATP, molecules). The proton (H+) gradient, and thus ∆m, originates from the 
accumulation of H+ in the intermembrane space (IMS) via active pumping from the mitochondrial 
matrix (see Figure 6).  
During intrinsic apoptosis, direct or indirect (e.g., as secondary damage after Ca2+ release from the 
ER) mitochondrial damage is characterized by a loss of ∆m. Depletion of the H+ gradient has been 
classically described as the consequence of two events: (1) impaired oxidative phosphorylation  
(e.g., by direct inhibition of electron transport chain complexes) and (2) formation/opening of any of 
the pores in the mitochondrial membrane system, such as the permeability transition pore (PTP), or 
Bax/Bak pores. Moreover, mitochondrial outer membrane (OM) permeability also drives the release of 
several pro-apoptotic proteins, including cytochrome c, Smac/DIABLO, HtrA2/Omi, apoptosis 
inducing factor (AIF), and endonuclease G [14,25].  
According to the classically accepted, though controversial, model, mitochondrial permeability 
transition (MPT) is based on opening of the PTP protein complex. Classical (vs. newly proposed) PTP 
(Figure 3) is a protein complex formed by the voltage-dependent anion channel (VDAC) located in the 
mitochondrial OM, the adenine nucleotide translocator (ANT) in the mitochondrial IM, cyclophilin D 
(CypD) in the mitochondrial matrix, and several other proteins at contact sites between the 
mitochondrial outer and inner membranes [26,27]. Despite the fact that most of the data are from  
in vitro studies, cytosolic Ca2+, low ATP, and reactive oxygen species (ROS) are the most accepted 
inducers of PTP opening, whereas cyclosporin A reverts the opening in most cases by sequestering 
CyD in the mitochondrial matrix [27]. Current data, however, indicate that VDAC is dispensable for 
MPT-mediated cell death [28]; on the other hand, CyD is gaining importance in mitochondria-
mediated cell death and especially, in ischaemia/reperfusion-mediated cardiac injury [29,30]. 
Nevertheless, recent studies indicate that CyD is not a common mediator in mitochondrial-mediated 
apoptosis and may be primarily involved in ROS or Ca2+ overload-induced necrotic cell death [30].  
Consequently, a second PTP-model has been proposed (Figure 3) in which VDAC is not a part of 
the PTP complex and mitochondrial phosphate carrier (PiC) is incorporated [31]. Therefore, not just 
the composition of the PTP but also its role in cell death processes is now under discussion. In general, 
PTP opening is known to result in the diffusion of low-molecular weight solutes (up to 1.5 kDa) across 
the inner membrane (IM), resulting in mitochondrial swelling and a loss of ∆m. In this scenario, 
rupture of the OM would be a consequence of IM swelling [27,31]. Interestingly, Bcl-2 family 
members seem to control MPT; Bcl-2/Bcl-XL has been shown to inhibit VDAC and ANT activity in 
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liposome experiments [27], but the relevance of this data is difficult to evaluate in the absence of a 
clear working model. 
Bak and Bax belong to the Bcl-2 protein family. This family includes a large number of pro- and 
anti-apoptotic proteins that share one or more Bcl-2 homology (BH) domains, which is important for 
heterodimeric interactions among members of the Bcl-2 family [13,32]. The founding member of the 
family, the proto-oncogene Bcl-2, was first identified in the 1980s [33,34]. Bcl-2 expression was 
shown to block cell death, unlike other proto-oncogenes known at that time that typically promoted 
cellular proliferation [35]. The first pro-apoptotic homolog, Bax, was identified some years later by its 
interaction with Bcl-2 [36]. The Bcl-2 family currently comprises roughly 20 members that are 
classically divided into three main groups based on their pro- or anti-apoptotic function and the 
presence of BH domains: Group I consists of anti-apoptotic Bcl-2 members (e.g., Bcl-2, Bcl-XL,  
Mcl-1), Group II contains BH-1, BH-2 and BH-3 presenting pro-apoptotic members (e.g., Bax, Bak) 
and Group III comprises BH-3 only members (all of them with pro-apoptotic function, such as Bad or 
Bid) [37].  
Figure 3. Comparison of the classical (left side) and novel models (right side) of the 
mitochondrial permeability transition pore (PTP). The role of hexokinase (HK), peripheral-
type benzoazepine receptor (PBR) and mitochondrial phosphate carrier (PiC) in the 
mitochondrial transition pore formation/function are still controversial [27,31]. 
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According to the generalized rheostat-model [38], upon stimulation, the ratio of anti-and  
pro-apoptotic Bcl-2 family members (e.g., Bcl-2/Bax) sets the threshold of susceptibility to apoptosis. 
Briefly, the pro-apoptotic Bak seems to be inserted into the OM even when inactive [39], whereas Bax 
monomers can be found in the cytosol or loosely associated with the OM when not activated. Bax 
translocation to the mitochondrial OM takes place during the activation process [32,40]. At the 
mitochondrial level, the interaction of anti-apoptotic (e.g., Bcl-2) and pro-apoptotic members  
(e.g., Bax) appears to inhibit Bax-Bak-mediated pore formation at the mitochondrial OM, preventing 
∆m loss and the release of pro-apoptotic proteins (e.g., cytochrome c, Smac) into the cytosol  
(Figure 2). (For a review see [32]).  
The release of mitochondrial IMS proteins (i.e., cytochrome c, Smac/DIABLO, HtrA2/Omi, AIF, 
and endonuclease G) leads to activation of the execution phase. Once in the cytosol and in the 
presence of dATP/ATP, cytochrome c binds and activates apoptotic protease-activating factor 1  
(Apaf-1) and procaspase-9, forming the apoptosome. Apoptosome formation is required for 
procaspase-9 activation and caspase-3/caspase-7 activation (for a review see [41]). On the other hand, 
Smac/DIABLO and HtrA2/Omi have been reported to inhibit cytosolic inhibitor of apoptosis proteins 
(IAPs) [14], which block caspase-9, -3, and -7 activation [42]. The remaining IMS proteins (i.e., AIF 
and endonuclease G) are in charge of DNA fragmentation and/or chromatin condensation in the 
nucleus, forming the typical apoptotic “DNA ladder” structure. Among the endonucleases, cytosolic 
caspase-activated DNase (CAD) is involved in the caspase-dependent cell death mechanism, whereas 
AIF and endonuclease G induce caspase-independent cell death [14]. 
Despite being a canonical intrinsic apoptotic pathway, mitochondria are far from the only elicitor 
organelles. As summarized in Figure 2, ER stress can also trigger intrinsic apoptosis through a pathway 
generally, though not compulsorily, involving secondary mitochondrial damage. Furthermore, DNA 
damage may also lead to the activation of intrinsic apoptosis as briefly described in a following section.  
4.2.2. Endoplasmic Reticulum-triggered Intrinsic Apoptotic Pathway 
Anti-apoptotic Bcl-2 members, such as Bcl-2 itself or Bcl-XL, can be found not just at the 
mitochondrial OM, but also at the ER (Figure 2). Pro-apoptotic Bax/Bak has also been found at the 
ER, and recent work supports the importance of the ER and ER-localized Bcl-2 family proteins as 
intrinsic apoptotic pathway checkpoints [13,22,24]. The ER is the main organelle for Ca2+ storage and 
protein synthesis and the first stop for proper polypeptide folding. When the capacity of the ER to fold 
proteins properly is compromised or overwhelmed (also known as ER stress), the unfolded protein 
response (UPR) is activated. Sustained or strong ER stress leads to metabolic arrest, which is followed 
by autophagy or the induction of apoptosis [22,24,43]. Ca2+ release from the ER has long been known 
to play a secondary messenger role in the induction of mitochondrial damage. Recent studies indicate 
Bcl-2 family members as guards that control apoptosis originating with the ER (through Ca2+ efflux 
regulation), as well as autophagy [22]. However, Bcl-2 family proteins do not merely act at the 
mitochondrial level.  
4.2.3. Nucleus (DNA Damage) Triggered Intrinsic Apoptotic Pathway 
The capacity of DNA damage to induce apoptotic cell death is based on three main observations [44]: 
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 The hypersensitive apoptotic responses of DNA repair-deficient cells (e.g., cell lines 
defective in O6-methylguanine-DNA methyltransferase (MGMT)) 
 The ability of modified nucleotide precursors incorporated into DNA to induce apoptosis 
 Electroporation of restriction enzymes into cells induces double strand breaks (DSBs) in 
DNA that trigger apoptosis but not necrosis  
Despite being the better-known type of DNA damage, DNA DSBs are far from the only type of 
DNA damage. In fact, DNA single strand breaks, O6-methylguanine formation, base N-alkylations, 
bulky DNA adducts, DNA cross-linking, and lesions caused by O6-chloroethylating agents (such as the 
anticancer drug cisplatin) may or may not cause DSBs but induce programmed cell death [44].  
Thus, nuclear DNA damage is another example of an intrinsic apoptotic pathway, in which the 
DNA repair system and protein-modifying enzyme poly(ADP-ribose) protein (PARP)-1 play a critical 
role [45]. PARP-1, also known as poly(ADP-ribose) synthetase and poly(ADP-ribose) transferase, is 
an abundant nuclear protein involved in the DNA base excision repair (BER) system. In the presence 
of mild DNA damage, PARP-1 has been shown to bind DNA breaks and transfer 50–200 residues of 
poly(ADP-ribose) to itself and acceptor proteins [46]. In contrast, excessive DNA damage generates 
large branched-chain poly(ADP-ribose) polymers, leading to the activation of a cell death program not 
yet fully characterized (and applied mainly to cells in the nervous system). According to the most 
common hypothesis, PARP-1-mediated cell death involves energy depletion [47] and AIF 
translocation from the mitochondria. However, the precise mechanism of PARP-1-dependent AIF 
translocation remains unclear [45].  
A better characterized and more generalized pathway is the one following DSBs and triggered by 
ataxia telangiectasia mutated (ATM) and ataxia telangiectasia and Rad3-related (ATR) protein 
activation [48]. Downstream of ATM activation, other proteins (i.e., CHK1, CHK2, MDM2, H2AX, or 
the well-known tumor suppressor p53) amplify the signal, leading not only to cell death, but also cell 
cycle arrest. Briefly, ATM-dependent p53 phosphorylation stabilizes p53; further cell cycle arrest by 
downstream up-regulation of the cyclin-dependent kinase inhibitor p21 or the induction of apoptosis, 
which occurs via the activation of several pro-apoptotic proteins (e.g., Bax or p53 up-regulated 
modulator of apoptosis (PUMA)), seems to be dependent on the p53 activation level. In the absence of 
active p53, which is a common mutation among cancer cells, CHK1 and CHK2 have been described as 
inducing apoptosis (not cell cycle arrest) through a pathway involving p73 activation [44].  
4.2.4. Mitochondria, ER, Nucleus: Why Not Another Organelle? 
Cells are well-organized and compartmentalized entities in which different organelles play distinct 
and indispensable roles. Nevertheless, discoveries during the last few years support the importance of 
communication and interaction between organelles for appropriate cell function and fates. Regarding 
apoptotic cell death, organelle and pathway interactions are summarized in Figure 2. Plasma 
membrane receptors, mitochondria, the ER, and nucleus have been shown to interact in the complex 
cellular death process. Information is still lacking concerning the possible role of Golgi or lysosomes 
in the activation of intrinsic apoptosis.  
From a simplistic point of view, the Golgi apparatus is the glycosylation center and vesicular 
trafficking coordinator in cells. In fact, the strongest evidence of the Golgi apparatus as a point of 
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apoptosis induction is the induction of apoptosis by α-mannosidase II inhibition [23]. Despite the lack 
of well known Golgi-specific stressors, local caspase-2 [49] and GD3 synthase activation, which is 
involved in ganglioside synthesis [50], are Golgi-damage responses that have been characterized. GD3 
is a complex glycolipid belonging to the sphingolipid family, generally described as sphingoid-based 
lipids (for a review see [51]). As pointed out by Hicks and Machamer [52], an interesting possibility in 
Golgi-mediated stress signaling could be the mediation of lipid scrambling in the Golgi membrane 
bilayers, similar to phosphatidylserine exposure at the plasma membrane during apoptosis. GD3, 
which is normally synthesized on the luminal face of the Golgi membranes, translocates to the 
mitochondria during apoptosis, where it is thought to induce MMP [53,54]. Interestingly, if active 
GD3 synthase is retained in the ER, GD3 is not transported to the mitochondria and the apoptotic 
stimulus is abrogated [55]. Another role of the Golgi in apoptotic cell death is linked to the presence of 
TNFR-1 [56] and Fas receptor/APO-1/CD95 [57] in this organelle. Nevertheless, whether the death 
receptors translocate to the plasma membrane upon apoptotic stimulus, or whether the plasma 
membrane-initiated death signal is transduced to the Golgi along the endocytic route, is unclear [58].  
Lysosomes, cellular “garbage bins” or “suicide bags”, may also be involved in apoptotic cell death. 
Lysosomes contain large amounts of catabolic hydrolases with optimum acidic pH, and their roles in 
autophagy, apoptotic cell clearance, and cell death have been extensively studied over the last few 
years [23,59]. Massive lysosomal membrane rupture has been found to lead to necrotic cell death, 
whereas moderate lysosomal membrane damage has been shown to induce apoptotic cell death [60,61]. In 
fact, lysosomal membrane permeabilization (LMP) is now considered a parallel phenomenon to MMP. 
Moreover, several lysosomotropic detergents (e.g., MSDH, siramesine), oxidative stress, sphingosine 
(backbone of the sphingolipid structure), and anticancer drugs (e.g., paclitaxel, etoposide, resveratrol), 
among others, have been reported to induce LMP [59]. As an example of the role of the lysosome in 
apoptotic cell death, hereditary deficiencies in lysosomal enzymes, such as Farber’s disease (caused by 
ceramidase deficiency, resulting in ceramide accumulation), are characterized by increased apoptosis [62].  
Cathepsins (lysosomal proteolytic enzymes that include cysteine, serine, and aspartate proteases) 
have been extensively implicated in lysosome-mediated apoptotic cell death [59,63,64]. Proteases in 
this group are synthesized as inactive precursors, glycosylated post-translationally, and directed 
towards the lysosomal compartment by the mannose-6-phosphate receptors. Acid sphingomyelinase 
activity-mediated ceramide, one of the better-known cell death-inducing sphingolipids, has been 
described as the main cathepsin D activator in the lysosomal lumen [65], but characterization of the 
cathepsin-activating molecule has not advanced. Several studies point out an important role for 
cathepsins, especially cathepsin B, in TNF-mediated [66,67] and TRAIL-mediated [68] apoptosis. 
Cathepsin B has been suggested to be a substrate for caspase-8 in this pathway [66]. However, these 
results must be interpreted with caution due to experimental difficulties with the assays carried out in 
cell-free systems [64,69]. Furthermore, Klaric et al. [70] recently published a study in which 
cathepsins were not essential for TNF-induced cell death.  
In order to achieve their role as cell death effectors, activated cathepsins must be released into the 
cytosol where the pro-apoptotic cascade can be propagated by caspase-dependent or -independent 
pathways [59]. Again, there is not much information regarding cathepsin substrates in the cytosol. Bid, 
a pro-apoptotic BH3-only member of the Bcl-2 family, is the most characterized cathepsin  
substrate [63,64,69]. As already mentioned in Section 3.1, Bid has long been known as a caspase-8/10 
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substrate that links death receptor-mediated cell death to mitochondrial damage (Figure 2). Cathepsin-
mediated (especially cathepsin B, but also L, S, and K) Bid cleavage (tBid) and activation [71,72] 
represents a second role for Bid in the lysosomal to mitochondrial damage connection (Figure 2). 
Recently, Bid-deficient animals have been shown to undergo cathepsin-dependent cell death [73]. This 
finding suggests the presence of cathepsin substrates other than Bid. In agreement with this,  
Droga-Mazovec et al. [74] found that cathepsins also degrade the anti-apoptotic Bcl-2 proteins Bcl-2, 
Bcl-XL, Mcl-1, and XIAP.  
The role of caspases in the lysosomal-apoptotic pathways is controversial. Though several studies 
suggest caspase-8, and to a minor extent caspase-2, -3, or -9, as cathepsin substrates (summarized  
in [63]), other studies mention a possible experimental mistake as the source of false positive substrate 
detection [64,69]. However, several studies support caspase activation downstream from cathepsin 
release into the cytosol (for review see [59]).  
4.3. Perforin/Granzyme-mediated Apoptotic Pathway 
Special mention is required for the perforin/granzyme apoptotic pathway, a mechanism detected in 
cytotoxic T lymphocytes (CTL) and natural killer (NK) cells, which induce apoptotic cell death in 
neighbor “dangerous” (i.e., virus-infected or transformed) cells [14,75,76].  
CTL and NK cells are important members of the defense mechanism, a role that is achieved not just 
through the perforin/granzyme pathway, but also through a second mechanism involving the plasma 
membrane death receptor (e.g., Fas/Apo-1/CD95) pathway. Regarding the perforin/granzyme pathway, 
the mechanism engages a transmembrane pore-forming molecule (perforin) and the release of 
cytoplasmic granules containing serine proteases (granzymes) capable of cleaving and activating 
proteins (e.g., procaspase-10, inhibitor of CAD (ICAD)) on the target cell. Since the discovery of 
perforin in the early 1980s, several models have been proposed (summarized in [75]) for this 
mechanism, but it has yet to be fully characterized. According to current knowledge, granzymes A and 
B are the most important components within the granules [77] and both the caspase-dependent and -
independent pathways can be activated at the target cells [14,76] (Figure 4). 
Briefly, granzyme B activates proteins, such as procaspase-10 or ICAD [78,79], probably by 
cleaving them at aspartate residues [80]. Other reports indicate granzyme B-dependent cleavage of  
Bid [81], or even direct executer caspase-3 activation [82], as a mechanism of apoptotic death 
induction. On the other hand, granzymes A and M seem to activate the caspase-independent death 
pathway via direct DNA damage. In this case, granzyme A cleaves the SET complex, driving the 
release of NM23-H1, a tumor suppressor DNase [83].  
Though perforin is known to be required for granzyme-mediated apoptosis, the precise mechanism 
for granzyme uptake remains controversial. Perforin pore-mediated direct granzyme uptake and 
perforin/granzyme-including endosomal vesicle incorporation are just some of the proposed 
mechanisms (Figure 4) [76].  
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Figure 4. Perforin/granzyme-mediated apoptotic cell death. Despite specific cytotoxic T 
lymphocytes (CTL) and natural killers (NK), this type of apoptosis is essential for the 
defensive role of our immune system. Model A and Model B represent proposed strategies 
for granzyme introduction in the target cell. Perforin is required for the granzyme-mediated 
apoptotic death of the target cell but it is no clear whether it directly forms pores in the 
plasma membrane of the target cell (Model A) or whether perforin/granzyme internalization 
occurs via receptor-mediated endocytosis (Model B). Mannosa-6-phosphate receptor has 
been recently proposed as a candidate for this process (reviewed in [14,75,76]). 
 
5. Apoptosis-inducing Agents in Cancer Therapy 
The apoptotic death of tumor cells is always the desirable effect of therapeutic agents. Optimal 
treatment should be based on the specific alteration of the target cell compared to non-malignant cells. 
Nevertheless, this optimal scenario is rare in cancer; malignant progression of the cell may be caused 
by thousands of different modifications. In addition, tumor cells often have high proliferation rates 
that, together with their acquired immortality, provide a favorable atmosphere for mutations. 
Therefore, major efforts are focused on the detection of frequently altered pro-survival signaling 
pathways, whereas most classical chemotherapeutic agents and radiation pursue DNA damage and/or 
cell proliferation inhibition-mediated control of the disease (for a review see [84]). 
On the other hand, bioavailability (i.e., concentration of the active drug surrounding target tumor 
cells in the body) is often a limiting factor in chemotherapy, despite new nanoparticle-mediated drug 
delivery systems [85]. Achieving the desirable drug concentration is an essential aspect of 
chemotherapy as many drugs may induce different biological processes (e.g., cell cycle arrest, 
autophagy, or necrosis instead of apoptotic cell death [86,87]) in a dose-dependent manner.  
According to the 13th Anatomical Therapeutic Chemical (ATC) classification (corresponding to 
2010), antitumoral agents (L01 subclass) are divided into five different groups: (1) alkylating agents, 
(2) antimetabolites, (3) plant alkaloids and other natural products, (4) cytotoxic antibiotics and related 
substances, and (5) other antineoplastic agents (Table 2).  
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Table 2. Classification of antitumoral drugs according to their Anatomical Therapeutic 
Chemical (ATC) classification. 
A-Alkylating Agents 
AA-Nitrogen mustard analogues (e.g., methorethamine) 
AB-Alkyl sulfonates (e.g., busulfan) 
AC-Ethyelene imines or aziridines (e.g., thiotepa) 
AD-Nitrosoureas (e.g., carmustine, lomustine, semuestine) 
AG-Epoxides 
AX-Other alkylating agents 
B-Antimetabolites  
BA-Folic acid analogues (e.g., methotrexate) 
BB-Purine analogues (e.g., azathioprine, mercaptopurine) 
BC-Pyrimidine analogues (e.g., 5-fluorouracil, capecitabine, cytosine arabinoside) 
C-Plant Alkaloides and Other Natural Products 
CA-Vinca alkaloids and analogues (e.g., vinblastine, vinorelbine) 
CB-Podophyllotoxin derivatives (e.g., etoposide) 
CC-Colchicine derivatives 
CD-Taxanes (paclitaxel, docetaxel) 
CX-Other plant alkaloids and natural products (e.g., camptothecin) 
D-Cytotoxic Antibiotics and Related Substances  
DA-Actinomycines (e.g., actinomycin D) 
DB-Anthracyclines and related substances (e.g., doxorubicin, daunorubicin) 
DC-Other cytotoxic antibiotics (e.g., mitomycin C, bleomycin) 
X-Other Antineoplastic Agents 
XA-Platinum compounds (e.g., cisplatin, carboplatin, oxaliplatin)  
XB-Methylhydrazines 
XC-Monoclonal antibodies (e.g., edrecolomab-antiEpCAM-, cetuximab-antiErbB1-, 
rituximab-antiMS4A1 (CD20 antigen), bevacizumab-antiVEGF…) 
XD-Sensitizers used in photodynamic/radiation therapy 
XE-Protein kinase inhibitors (e.g., imatinib, erlotinib, sunitinib, nilotinib…) 
XX-Other antineoplastic agents (e.g., hydroxycarbamide, tretinoin, celecoxib…) 
XY-Combinations of antineoplastic agents 
ATC classification is based on the primary therapeutic use of the main active ingredient. In regard 
to chemotherapy design, two approaches are currently used: (1) classical drug synthesis based on the 
empirical chemopreventive/antineoplastic effect of certain compounds, often with natural origin  
(e.g., retinoic acid, a natural derivative of vitamin A) and (2) cell death-inducing agents designed with 
a focus on specific molecular targets with relevance on tumor cell survival (e.g., inhibitors of anti-
apoptotic Bcl-2 family members). Chu and DeVita [88] provided an extensive physician-oriented 
review of currently used chemotherapeutic drugs, including the mechanism of action, indications, drug 
manufacturers, and marketed names. 
5.1. Classical Chemotherapy: Against the Malignant Phenotype 
This group includes a long list of compounds that affect any of the tumorigenic characteristics of 
the cell (e.g., uncontrolled proliferation, immortality, acquired migration capacity, invasion) without a 
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precise (or known) molecular target. We will focus on chemotherapeutic agents that mainly lead the 
tumor cell to an apoptotic death (Table 3). 
Table 3. Classification of antitumoral drugs according to their cellular target. 
Classical Chemotherapy 
(without precise or known molecular target) 
Specific Molecule-Targeted Agents 
1. DNA damaging agents 
1.1. Platinum compounds (e.g., cisplatin, 
carboplatin, oxaliplatin) 
1.2. Alkylating agents (nitrogen mustards) 
1.3. Cytotoxic antibiotics (e.g., actinomycin 
D, anthracyclines, mitomycins, bleomycins) 
1. Bcl-2 (and related molecule) targeted 
compounds (e.g., AT-101, ABT-737,  
oblimersen sodium) 
2. Oxidative stress-mediated cell death 
inducers (e.g., 4-HPR, PEITC) 
2. DNA damaging agents 
2.1. Antimetabolites (e.g., methotrexate) 
2.2. DNA topoisomerase (I and II) inhibitors  
(e.g., camtothecins, podophyllotoxins) 
 
  3. Drugs to target DNA-damage repairing 
systems 
3.1. CDK inhibitors (e.g., UCN-01, XL844) 
3.2. PARP-1 inhibitors (e.g., AG014699) 
3.3. MGMT inhibitors (e.g., PaTrin-2) 
 
 4. Telomere/Telomerase-targeted anticancer 
drugs (BIBR1532, telomestatin, BRACO19) 
 
 5. Compounds to disrupt cytoskeleton dynamisn 
(Vinca alkaloids, taxanes, epothilones) 
 
 6. ER-stress response altering agents 
Proteasome inhibitors  
6.1. Proteasome inhibitors (e.g., bortezomib, 
salinosporamide A) 
6.2. Inhibitors of unfolded protein response (UPR) 
molecules (e.g., versipelostatin) 
 
 7. Kinases inhibiting agents 
7.1. Antibody-based therapies  
(e.g., beracizumab, trastuzumab) 
7.2. Small molecule-based therapies  
(e.g., imatinib, erlotinib, AZD1152, temsirolimus) 
 
 8. Others 
8.1. IAP inhibitors 
8.2. Lysosome permeabilization inducing agents 
8.3. Mitochondria-targeted compounds 
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5.1.1. DNA-Damaging Agents 
DNA-damaging agents are double-edged swords; they have a well-known carcinogenic capacity but 
are used as antitumoral drugs. Despite this negative aspect, this group is the largest among 
antineoplastic compounds (Figure 5). Far from simple, the term “DNA damage” includes a broad 
range of damage already mentioned in Section 3.2.3.  
Figure 5. Drugs targeting DNA, endoplasmic reticulum, or proteasome. The figure 
represents an overview of compounds aimed to induce tumor cell death by interacting with 
specific molecules (as shown in the figure) or by inducing DNA damage. 
 
 
Metal-based drugs, especially platinum compounds (L01XA group according to the current ATC 
classification), are perhaps the most characteristic DNA-damaging therapeutic drugs with cisplatin 
(cis-diamminedichloroplatinum (II)) as the pioneer member of the group. Metal-based drugs include 
not just platinum compounds, but also recently developed gold, ruthenium, and copper-based agents 
(for a general overview of the field, see [89]). Briefly, the antitumoral activity of platinum compounds 
is thought to rely on their ability to form different types of adducts with DNA, which blocks 
replication and transcription and ultimately drives cell death. Nevertheless, platinum compounds may 
also act through other mechanisms. Cisplatin, for example, has been shown to modulate several 
proteins by interacting with their thiol groups. Moreover, cellular detoxification of cisplatin seems to 
be mediated by its reaction with sulfur groups [90], although recent data argue against the generally 
accepted direct interaction between glutathione and cisplatin molecules as the principal mechanism [91]. 
Regarding cellular detoxification, intracellular glutathione levels have been linked to resistance against 
this compound [90]. Observed cisplatin-mediated oxidative stress may also be a consequence of its 
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capacity to “sequester ” reduced glutathione molecules [90,92]. (For a comprehensive review regarding 
cisplatin and other platinum compounds (i.e., carboplatin, oxaliplatin, Lipoplatin, Lipoxal, and 
nedaplatin), their current use in chemotherapy, adverse effects, or ongoing clinical trials see [93,94]).  
Alkylating agents (L01A group according to the ATC classification) include a long list of 
compounds with the capability to generate DNA base damage [84] via direct interactions that lead to 
DNA crosslinking, DNA strand breaks, and abnormal DNA base pairing. Similar to platinum 
compounds, a lack of discrimination between normal and tumor cells leads to important side effects 
upon treatment with alkylating agents. (For a complete review regarding better known alkylating 
agents (i.e., nitrogen mustards, ethylene imines, alkyl sulfonates, and nitrosoureas) see [95]. 
Cytotoxic antibiotics, such as actinomycin D, doxorubicin, and mitomycin C, are natural or natural-
derivative compounds with several applications, including chemotherapy. These compounds damage 
DNA or DNA-related processes via several mechanisms, such as binding specific DNA sequences 
(followed by inhibition of RNA polymerase-mediated mRNA synthesis), inhibiting topoisomerase 
activity (mentioned in Section 4.2.2.), or inducing DSBs [96,97]. According to the ATC classification, 
antitumoral antibiotics are divided into three different groups (Table 2): (1) actinomycins,  
(2) anthracyclines and derivatives, and (3) others.  
Actinomycin D, the most significant actinomycin, is a natural antibiotic produced by the bacteria 
Streptomyces antibioticus. Actinomycin D binds GC-rich DNA duplex sequences, non-duplex single-
stranded structures, and hairpin structures, consequently inhibiting RNA polymerase activity. The 
antibiotic was also recently shown to bind the cMyc oncogene promoter G-quadruplex structure, 
which would represent a novel mechanism for its antitumoral activity [97]. 
Anthracyclines, such as daunorubicin and doxorubicin (doxorubicin hydrochloride or Adriamicin), 
are naturally synthesized by different strains of the bacteria Streptomyces peucetius or semisynthetic 
(e.g., idarubicin and epirubicin) (for a comprehensive review see [96]). The mechanism of action 
involves, but is not limited to, (1) intercalation into DNA, (2) free radical generation, 3) DNA binding 
and alkylation, 4) DNA cross-linking, and 5) topoisomerase II inhibition [96].  
Mitomycins are a group of antibiotics isolated from Streptomyces caespitosus or Streptomyces 
lavendulae and present a high capacity for crosslinking DNA to 5´-CpG-3´ sequences [98]. Among 
mitomycins, mitomycin C exerts the highest activity against tumor cells and is commonly used in 
cancer therapy [99]. Reduction of this compound is necessary for its activation, a process that may 
drive superoxide production and, ultimately, oxidative stress. In fact, a deficiency of activating 
enzymes, such as NAD(P)H oxidoreductase, has been linked to the development of clinical resistance 
against mitomycin C [98]. Bleomycins are also synthesized by several Streptomyces species, and their 
antitumoral activity relies on sequence-selective, metal and oxygen-dependent oxidative cleavage of 
DNA and RNA molecules with subsequent induction of oxidative stress (for a review see [98]). 
5.1.2. Oxidative Stress-mediated Apoptotic Cell Death 
Imbalance among reactive oxygen/nitrogen species (ROS/RNS) production and neutralization 
creates an oxidative environment in the cell that may ultimately damage lipids, proteins, and 
DNA/RNA molecules. An oxidative environment and cancer have been often associated [100] based 
on the following observations: (1) ROS and oxidative stress may induce cancer; (2) transformed cells 
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appear to generate more ROS than normal cells; (3) cellular antioxidant systems (e.g., thioredoxin 
system) are often amplified in malignant cells; (4) the stimulation of cellular proliferation (e.g., by 
growth factors) often involves increased ROS production, and (5) partial selectivity of diverse 
antitumoral agents against malignant cells is based on the intrinsic augmented oxidative stress of 
tumor cells, as they act by pushing tumor cells beyond their capacity to handle such stress. Therefore, 
the relationship between oxidative stress and cancer is at least complex, and at some points 
controversial.  
A large number of antineoplastic treatments/compounds, such as cisplatin, mitomycin C, and 
radiation, induce an increase of the cellular ROS/RNS content, and this secondary effect may be 
involved in their anticancer activity, but it also represents a limiting factor in their therapeutic 
application by inducing important side effects. Free radical scavengers and antioxidants have been 
shown to decrease undesirable toxic effects [101,102], though they may also decrease the activity of 
the antitumoral drug, presumably whenever oxidative stress induction is an important mechanism of 
action [103]. Wang and Yi [104] reviewed the arguments in favor and against the use of pro-oxidant 
compounds in cancer therapy.  
Despite some controversial aspects, increased cellular ROS/RNS content (or decreases in the 
cellular antioxidant system) seems to be important for the induction of malignant cell death by several 
antitumoral drugs/treatments, including 4-HPR [105], 2-deoxy-D-glucose [106], NSC-741909 [107], 
arsenic trioxide, imexon, photodynamic therapy, -phenylethyl isothiocyanate (PEITC), and  
disulfiram [104]. Notably, many of these compounds still lack a precise mechanism or target molecule, 
though mitochondrial damage persists as the most common and evident effect (Figure 6; for a 
comprehensive review regarding the therapeutic potential of mitochondrial-damaging oxidative stress 
inducers see [108]).  
5.2. Specific Molecule-targeted Agents  
Understanding the molecular etiology of the disease and the intrinsic regulation of pro-survival 
pathways in the cell provides necessary tools for chemotherapeutic drug development. In this regard, 
imatinib (also known as CGP-57148(B) or STI-571, and marketed as Gleevec or Glivec) represents the 
first member of the specifically targeted drugs by inhibiting the tyrosine kinase enzyme ABL [109]. 
This and other examples will be classified according to their target proteins or enzymatic activities, 
with special emphasis on those with inherent pro-apoptotic activity (Tables 2 and 3). 
5.2.1. Strategies Against Bcl-2 and Related Anti-apoptotic Family Members 
Bcl-2 and related family members have been a potential therapeutic target since first being implied 
in tumor cell survival [35]. The previously mentioned “rheostat model” [38] supports the importance 
of down-regulating anti-apoptotic Bcl-2 family members (i.e., Bcl-2, Bcl-XL, Bcl-W, Mcl-1, Bcl-2A1, 
and Bcl-B) to promote apoptotic tumor cell death.  
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Figure 6. Drugs targeting mitochondrion or lysosome. The figure represents an overview 
of compounds aimed to induce tumor cell death by interacting with specific molecules (as 
shown in the figure), by inducing oxidative damage or permeabilization of the lysosomal 
membrane. 
 
Gossypol, a polyphenolic compound found in the cotton plant, was the first inhibitor of anti-
apoptotic Bcl-2 family members, such as Bcl-XL [110], to be described, though its antineoplastic 
effects have been known since the 1960s [111]. Being a naturally racemic mixture of (+) and (−) 
enantiomers, the levo (-) form has shown sustained growth-inhibitory effects in the presence and 
absence of serum (vs. the (+) form, which has decreased activity in the presence of serum [112]). In 
fact, (-)-gossypol enantiomer separation leads to R-(-)-gossypol-acetic acid (AT-101) development 
(Figure 6), which has shown high affinity to Bcl-2 and Mcl-1 [113].  
ABT-737 (A-779024), which was found in nuclear magnetic resonance (NMR)-based screening, is 
another example of Bcl-2, Bcl-XL, and Bcl-w-inhibiting molecules that do not initiate apoptosis but 
enhance the pro-apoptotic effects of other compounds [114]. Bioavailability problems have supported 
the discovery of another Bad-like BH3 mimetic compound, ABT-263, which is orally available, unlike 
ABT-737 [115]. These and other BH3 mimetic compounds act by sequestering Bcl-2 (or other anti-
apoptotic members) molecules (Figure 6) and, therefore, promote the activity of the pro-apoptotic 
members of the family (e.g., Bax, Bak, Bim).  
Molecular cloning of the Bcl-2 sequence [116,34] allowed the development of a unique type of  
Bcl-2 antisense oligonucleotide drug by the early 1990s [117] that is currently known as oblimersen 
sodium or G3139 (marketed as Genasense). This compound inhibits Bcl-2 protein synthesis by 
inactivating Bcl-2 mRNA (Figure 5) and has shown chemosensitizing effects in combination with 
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other conventional chemotherapeutic drugs, especially in chronic lymphocytic leukemia patients [118] 
(for a review see [113]). 
5.2.2. DNA-Damaging Agents 
Some DNA-damaging agents, known as antimetabolites, present clear target molecules and, 
therefore, must be included in this section. Antimetabolites can be defined as “substances that closely 
resemble metabolites and therefore interfere with physiological reactions involving them” [119]. 
Antimetabolites applied in chemotherapy (Tables 2 and 3) act by interfering with DNA synthesis. 
Briefly, folic acid analogues or antagonists, such as methotrexate or pemetrexed, inhibit dihydrofolate 
reductase [119,120], depleting cells of reduced folates, which are required for purine synthesis. Other 
antimetabolites are purine or pyrimidine analogues, “fraudulent” nucleotides that are incorporated into 
DNA during DNA synthesis and lead to defective DNA replication (Figure 5). In this regard, 
antimetabolites may not only induce apoptotic cell death, but also slow down the proliferation rate or 
cell cycle arrest (for a review see [119,120]). 
Inhibition of DNA topoisomerases (I and II) is another well documented antitumoral strategy that 
leads to DNA damage, cell cycle arrest, and activation of DNA repair pathways and may result in 
apoptosis or other types of cell death [121,122]. Briefly, topoisomerases (Figure 5) are in charge of 
winding and unwinding DNA, a process required for DNA transcription and replication (for a review 
see [123]). Type I topoisomerases cleave only one strand of the DNA, whereas type II topoisomerases 
cleave both strands, generating DSBs.  
Camptothecins (e.g., topotecan, SN-38, CPT-11/irinotecan) represent the better known 
topoisomerase I (topI) inhibitors, together with indolocarbazoles and indenoquinolines (for a review 
see [124,125]). Camptothecin, which is isolated from the Camptotheca acuminata tree, and its 
derivatives are non-competitive inhibitors of topI; they form a ternary complex by binding top1 and 
the cleaved DNA. Indolocarbazoles also prevent DNA religation, but unlike camptothecins, DNA 
binding can be via intercalation. 
Topoisomerase II (topII) inhibitors are classified into topII poisons and topII catalytic inhibitors. 
TopII poisons are defined as “drugs targeting Top2 that lead to elevated levels of Top2: DNA covalent 
complexes”, whereas catalytic inhibitors basically block the activity of the enzyme with no 
involvement of DNA damage [122]. Antineoplastic application of topII inhibitors rely on the topII 
poison group, which includes DNA intercalators, such as anthracyclines (e.g., doxorubicin; also 
mentioned in Section 4.1.1.), and non-intercalators, such as podophyllotoxins (e.g., etoposide and 
teniposide).  
5.2.3. Disruption of the DNA-Damage Repair System 
As mentioned above, most anticancer therapies (chemotherapeutic or radiation therapy) are based 
on the induction of DNA damage as the mechanism to ultimately activate cell death pathways. 
Nevertheless, the presence of DNA damage is not an exclusive consequence of anticancer therapies, 
but a condition that often takes place during complex DNA replication and translation processes, as 
well as during the cell lifespan. Due to the mutagenic/lethal potential of DNA damage, cells have 
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evolved a complex net of DNA repair systems that serve to ensure DNA integrity but may also reduce 
the effect of many antitumoral treatments.  
Depending on the type of DNA lesion, different types of repair systems are activated [126]. The 
main systems in mammals are the following: 
 Base excision repair (BER) primarily repairs non-bulky lesions with no major distortion of the 
DNA double helix structure (e.g., bases with alkylation, oxidation or ring saturation damage, 
deaminated bases, DNA SSBs). 
 Nucleotide excision repair (NER) removes damage or incorrect bases in a 24–32 base pair 
oligonucleotide manner and then mends the resulting gap (e.g., bulky DNA lesions with 
potential for blocking DNA replication). 
 Transcription coupled NER (TC-NER) repairs DNA damage specifically on the RNA 
polymerase II-transcribed strand. Damage recognition occurs when RNA polymerase II stalls at 
a DNA lesion. 
 Nonhomologous end joining (NHEJ) repairs DNA DSBs when they occur outside a replication 
fork and not in S phase. 
 Homologous recombinational repair (HRR) repairs DNA DSBs when they occur at replication 
forks and when cells are in S phase, and contributes to the repair of DNA interstrand cross-
links.  
 Mismatch repair (MMR) recognizes and repairs base-base mismatches and insertion/deletion 
loops that arise during DNA replication (e.g., certain damage caused by ROS and alkylating 
agents). 
The inhibition of DNA repair systems, especially with DNA damage-inducing drug administration, 
seems to be a promising strategy against cancer. Until now, there are three targeted controlling/repairing 
systems (Figure 5): (1) cell cycle checkpoint proteins (e.g., cyclin-dependent kinase 1 and 2 (CDK1 
and CDK2)), (2) PARP-1, or (3) O-6-methylguanine-DNA methyltransferase (MGMT).  
Ashwell and Zabludoff [127] summarized the current knowledge regarding CDK1 and CDK2 
inhibitors, such as UCN-01, XL844, and AZD7762. As described in Section 3.2.3, the activation of 
ATM and ATR functions as a sensor of DSBs and SSBs. CDK1 and CDK2 are ATM and  
ATR-downstream effectors and play a critical role in the cell cycle by promoting cell cycle arrest in 
order to gain time for DNA repair and cell survival. Therefore, the inability to activate CDK1 and/or 
CDK2 upon DNA damage provokes the activation of apoptotic pathways as the natural alternative for 
the cell to ensure the elimination of damaged cells.  
PARP-1, which is discussed in Section 3.2.3, is the most abundant form of the PARP family and 
located in the nucleus, where it works as a sensor for SSBs [128]. Activation requires binding to DNA 
strand breaks, which is required to recruit proteins that form the BER complex [129].  
The development of PARP-1 inhibitors was based on the “single strand DNA break-inducing” 
capacity of many of the previously described antineoplastic drugs (e.g., topI inhibitors) and can be 
considered the first (though still young) chemopotentiating agents [130]. Drew and Plummer [129] 
provide an updated review of PARP-1 inhibitors from different pharmaceutical companies that are 
already in clinical trials, including AG014699, KU59436 (AZD2281), and ABT-888. 
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MGMT is an essential enzyme for repairing O6-alkylguanine-based DNA lesions in normal tissues 
and, therefore, a key element in resistance against O6-alkylating agents, such as temozolomide or 
dacarbazine. MGMT is considered a suicide enzyme because of its mechanism of action; it transfers 
the DNA-damaging alkyl group to a cysteine in its own active center, which restores the guanine base 
on the DNA but inactivates the enzyme (for a review see [131]). Inhibition of MGMT activity 
represents a strategy for enhancing the effect of several antineoplastic alkylating agents and, therefore, 
a suitable goal to pursue. Efforts to design MGMT inhibitors have focused on the development of 
guanine analogues aimed at irreversibly inactivating MGMT. The first guanine analogue was  
O6-methylguanine [132,133]. Nevertheless, the excessive concentrations required, as well as other 
problems, led to the design of other alternatives, such as O6-benzylguanine [134]. O6-benzylguanine 
established a platform for developing other inhibitors based on molecular changes, including the 
addition of methyl- or bromo- groups [131] or conjugation with glucose [135]. PaTrin-2 (O6-(4-bromo-
thenyl)guanine (4BTG, PatrinTM, Lomeguatrib) is perhaps the most advanced MGMT inhibitor to  
date [136], though there is still a long way to go on this field. 
5.2.4. Telomere/Telomerase Targeted Anticancer Drugs 
Telomeres are essential to the maintenance of chromosomal integrity and are located at the ends of 
chromosomes. Human telomeres consist of 5´-TTAGGG-3´ sequence tandem repeats that shorten each 
round of cell division due to the inability of DNA polymerase to fully replicate the end of 
chromosomes [137]. In most somatic cells, continuous telomere shortening triggers replicative 
senescence and, ultimately, cell death (for a review see [138]). Nevertheless, mammalian germline and 
early embryonic cells express an RNA-dependent DNA polymerase complex (telomerase) capable of 
adding multiple copies of the 5´-TTAGGG-3´ motif to the end of the telomere [137]. Moreover, 
telomerase has been measured as being over-expressed in roughly 85% of human cancers [139], which 
partially explains their characteristic immortal phenotype. Based on these data, telomerase inhibition 
represents a possible strategy for inducing cancer cell death via the activation of senescence by 
compounds that a) inhibit its catalytic activity (e.g., BIBR1532), b) inhibit the expression of 
telomerase components, or c) alter post-translational modifications of the enzyme [140]. 
Telomeres are mainly formed by double-stranded DNA with a short single stranded 3´ overhang 
located at the end of each telomere. The overhang is extremely sensitive to degradation and, at the 
same time, required by the telomerase as a template for further telomere elongation. The overhang is 
usually protected from degradation by a protein complex known as the telosome or shelterin. The 
telosome/shelterin complex also controls telomere elongation by regulating the accessibility of 
telomerase to the overhang [140].  
G-quadruplexes are guanine-based secondary DNA structures of potential interest to antitumoral 
compound design based on the incapability of telomerases to elongate these structures [141]. 
Therefore, G-quadruplex-interacting agents can also be evaluated as potential anticancer compounds. 
Some of these compounds, including telomestatin, have been shown to induce replicative senescence, 
whereas others (e.g., BRACO19, RHPS4) seem to induce the apoptotic death of tumor cells via 
mechanisms that may involve the activation of the DNA damage response (for a review see [140,141]). 
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5.2.5. Disruption of the Cytoskeleton Dynamism as an Anticancer Strategy 
The cytoskeleton, which is formed by microfilaments, intermediate filaments, and microtubules, is a 
dynamic structure essential for cell shape, intracellular vesicular/organelle trafficking, and proper cell 
division. Inhibitors of correct microtubule assembly/disassembly are generally named antimitotic 
agents based on the relevance of microtubules to spindle formation and, ultimately, cell division. 
Microtubules are basically α and β-tubulin polymers, and most antimitotic agents are classified as 
tubulin-interacting agents [124]. 
Two major mechanisms are known for tubulin interaction-mediated microtubule disruption:  
(1) inhibition of tubulin polymerization, and lack of microtubule formation, and (2) stabilization of the 
polymerized tubulin. Agents that act through the inhibition of tubulin polymerization are those that 
bind to -tubulin at the colchicine site (e.g., podophyllotoxin, 2-methoxyestradiol, and heterocyclic 
ketones, including some flavonoids) or interact with the vinca domain (e.g., vinca alkaloids such as 
vinblastine, vincristine, and vinorelbine). Taxanes (e.g., paclitaxel and docetaxel), which are diterpenes of 
plant origin, represent the better known group of polymer tubulin-interacting molecules [124,142]. 
Epothilones (epoxides, olefins, and derivatives) and discodermolide, though less known, also stabilize 
the polymerized tubulin structure. Other novel anti-microtubule agents that are gaining interest are 
dolastatin, halichondrin B, and hemiasterlin, all of which originate from marine sponge or sea  
hare [142,143].  
Neurotoxicity caused by classical anti-microtubule agents, such as taxanes, has supported studies 
investigating other non-tubulin-interacting-antimitotic compounds. Inhibitors of the aurora kinases 
(e.g., VX-680, AZD1151), polo-like kinase 1 (PLK1) (e.g., BI 2536), kinesin spindle protein (KSP) 
(e.g., ispinesib), and centromeric protein E (CENPE) (e.g., GSK-923295) are under current 
development (for a review see [143]).  
5.2.6. ER-Stress Response Altering Agents 
Proteasome inhibitors are the better characterized members of this group, though recent studies 
suggest that ER unfolded protein response molecules, such as glucose-regulated protein 
78/immunoglobulin heavy-chain binding protein (GPR78/BiP), could also be suitable targets against 
cancer (Figure 6).  
The (26S) proteasome represents the main non-lysosomal protein degradation pathway in the cell 
and, consequently, a crucial mechanism for protein turnover. This multicatalytic complex is composed 
of two main structures: the 20S particle, the core where proteolysis occurs, and the 19S particle 
complex, which is in charge of ubiquitinated substrate recognition and unfolding [144]. The protein 
degradation capacity of the proteasome relies on three major activities: (1) chymotrypsin-like activity 
that cleaves after hydrophobic amino acids; (2) a trypsin-like activity that cleaves after basic amino 
acids, and (3) a post-glutamyl peptide hydrolyzing or caspase-like activity that cleaves after acidic 
amino acids [145]. 
Proteasome inhibitors were first designed to study the proteolytic activities of this enigmatic 
complex. Later, the capacity of these compounds to induce apoptotic cell death in chemotherapy-
sensitive and resistant cell lines, and the fact that they preferentially attack malignant cells [146] 
started a new field: the use of proteasome inhibitors as antitumoral drugs (reviewed by [147,148]). 
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From a general point of view, proteasome inhibitors can be classified into two groups: (1) peptide-
based inhibitors resembling proteasome substrate proteins (e.g., bortezomib (Velcade), calfilzomid 
(PR-171) or MG132) and (2) natural products (e.g., lactacystin or salinosporamide A (NPI-0052)).  
Different compounds seem to target distinct active sites of the 20S proteasome. MG115 and MG132 
belong to the group of classic reversible inhibitors of chymotrypsin-like activity. Despite possible 
problems with non-specificity, lactacystin (obtained from the bacteria Streptomyces lactacystinaeus) 
has been a classical compound for irreversible 20S inhibition [147]. Other compounds, such as 
bortezomib, reversibly inhibit chymotrypsin-like activity and caspase-like activity (though to a minor 
extent) via non-covalent complex formation. On the other hand, calzomib and salinosporamide A-
mediated inhibition of chymotrypsin-like activity is irreversible [149].  
The UPR, as indicated by its name (defined in Section 4.2.2.), is a mechanism activated in the ER 
upon accumulation of unfolded/misfolded proteins. GPR89/BiP, PRKR-like ER kinase (PERK), 
inositol-requiring kinase 1 (IRE1), and activating transcription factor 6 (ATF6) are upstream from a 
complex signal transduction pathway that restores ER balance by (a) increasing the expression of ER 
chaperones; (b) arresting mRNA translation in order to temporarily decrease activity in the ER;  
(c) accelerating proteasome-mediated damaged protein degradation, or (d) increasing autophagic 
protein degradation [150]. 
An enhanced UPR (especially GPR78 expression) has been observed in numerous tumors to the 
point of being considered a novel biomarker of tumor behavior [151]. Already in 2004, a novel 
compound of microbial origin was isolated from a culture broth of Streptomyces versipellis and was 
capable of suppressing the activation of the GRP78 promoter. The compound was versipelostatin 
(Figure 5) [152]. Current GPR78 modulators include non-selective compounds, such as genistein, as 
well as highly selective compounds, such as versipelostatin, novel derivatives of versipelostatin, or the 
bacterial AB5 subtilase cytosine, which cleaves GPR78 at a single amino acid [151,153]. All of the 
compounds have high chemotherapeutic potential that must be proven in future studies. 
5.2.7. Kinase Inhibiting Agents 
Reversible phosphorylation processes are well known mechanisms for protein activation/deactivation 
and, therefore, essential in signaling pathways. Proteins in charge of transferring phosphoryl groups to 
target proteins are termed kinases, whereas dephosphorylation processes rely on phosphatases. 
Moreover, the de-regulation (e.g., sustained activation) and over-expression of different kinases is 
involved in several pathologies, including rheumatoid arthritis, cardiovascular disease, neurodegenerative 
diseases, and cancer [154]. Focusing on cancer, Bcr-Abl1 is a clear example of an aberrant fusion 
protein as the product of a gene formed by the fusion of the partial abl1 and bcr genes. Bcr-Abl1 
protein is a de-regulated, constitutively activated protein with enhanced tyrosine kinase activity and 
involved in pro-survival and anti-differentiation pathways. Bcr-Abl1 has the capacity to inhibit tumor 
suppressors (e.g., p53) and to induce DNA damage. The protein is thought to be involved in the 
initiation steps of chronic myeloid leukemia and represents one of the first successes of protein-
targeted drug synthesis (i.e., imatinib) [155]. The current view of protein kinases in cancer is 
composed of a long list of altered enzymes and targeted compounds [156].  
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Cancer-related protein kinase classification includes two main groups: (1) tyrosine kinases, which 
phosphorylate tyrosines of the target proteins, and (2) serine-threonine kinases, which phosphorylate 
either serine or threonine [156,157]: 
Tyrosine kinases: 
1.1. Non-receptor tyrosine kinases:  
 Abl (v-abl Abelson murine leukemia viral oncogene homolog 1) 
 Bcr-abl1 (aberrant fusion protein) 
 Focal adhesion kinase (FAK) 
 Janus kinase (JAK)  
 Src 
1.2. Receptor tyrosine kinases: 
 Anaplastic lymphoma kinase (Alk) 
 Epidermal growth factor receptor (EGFR) family 
 Fibroblast growth factor receptor (FGFR) family 
 Platelet-derived growth factor receptor (PDGFR) family, also known as MDGF, GSM, 
FDGF, ODGF, MDF, OBIF, T47Dfactor, and GDGF 
 Vascular endothelial growth factor (VEGFR) family  
 Insulin growth factor receptors (IGFR) 
 c-kit (CD117) 
 Flt3 (fms-like tyrosine kinase receptor-3) 
 Met (mesenchymal/epithelial transformation factor/hepatocyte growth factor receptor) 
 Ret  
Serine/threonine kinases:  
 Aurora kinases 
 CDKs  
 Chk (checkpoint kinases) 
 Extracellular signal-regulated kinase 5 (ERK5) 
 Mitogen-activated protein kinase (MAPK/MEK) 
 mTOR (mammalian target of rapamycin) 
 Nek (NIMA-related kinases) 
 Phosphoinositide-dependent kinase 1 (PDK1) 
 Phosphatidylinositol 3-kinase (PI3K) 
 Protein kinase B (PKB, also known as Akt) 
 Protein kinase C (PKC) family 
 Polo-like kinases (Polo-box domain containing kinases) 
 Raf kinases 
 Ras 
 ROCKs (Rho kinases) 
In general, kinase inhibitors can be classified as monoclonal antibodies or targeted small molecule 
inhibitors. Monoclonal antibodies are theoretically suitable for targeting membrane receptor tyrosine 
kinases (Figure 7), though small-molecule inhibitors seem to offer more advantages, especially in 
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regards to fewer adverse effects compared to antibodies or other common antitumor drugs [156]. The 
mechanism of action of small molecule inhibitors is based on affinity for either ATP-binding sites or 
allosteric sites. Affinity to kinase-specific allosteric sites represents the best scenario in therapy as 
ATP-binding sites are not exclusive to a certain kinase.  
Figure 7. Schematic mechanism for receptor tyrosine kinase inhibition. Antibody-
mediated inhibition of the ligand-binding domain and inhibition of the ATP-binding 
domain are main strategies for receptor tyrosine kinase inhibition. 
 
Currently available antibody-based therapies include beracizumab to block VEGFR and 
trastuzumab (commercially launched as Herceptin) against HER2, a member of the EGFR receptor 
tyrosine kinase family. Other therapies, including the EGFR blockers GA 201, pertuzumab, and 
zalutumumab; IGF-1R ligands AMG 479, BIIB 022, cixutumumab, figitumumab, and robatumumab; 
and VEGFR signaling pathway members MetMAb, SCH 900105 (against Met), alacizumab pegol, 
IMC 18F1, and ramucirumab, belong to different pharmaceutical companies and are undergoing 
clinical trials [156].  
Small molecule-based strategies include a long list of compounds [156]. For simplicity, we briefly 
describe the rationale behind some of these antitumoral drugs: 
Tyrosine kinase inhibitors are the largest group of kinase-inhibiting small molecules. Most of the 
compounds act, as mentioned above, by blocking the ATP-binding site of the target molecule  
(Figure 7) [158]. Imatinib mesylate (STI571 or Gleevec) was the first member of this group and, as 
mentioned above, designed to block the aberrant fusion protein Bcr-abl, which is present in nearly all 
patients with chronic myeloid leukemia. Moreover, imatinib has been shown to inhibit c-kit and 
PDGFR tyrosine kinases, which are thought to play an important role in gastrointestinal stromal tumor 
(GIST) formation. Unfortunately, disease relapse involving acquired resistance to imatinib has been 
observed in many patients and forced the development of alternative treatments, such as  
sunitinib [159,160]. Regarding chronic myeloid leukemia, mutations in the Bcr-abl kinase domain 
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seem to be the most common mechanism underlying acquired resistance [161]. Dasatinib and nilotinib 
are also among the current alternatives for imatinib-resistant disease. Dasatinib is a non-specific Bcr-
abl inhibitor capable of binding both active and inactive conformations of Bcr-abl, whereas nilotinib is 
an imatinib-related molecule specific to the inactive conformation of Bcr-abl [162]. 
Other tyrosine kinase inhibitors include EGFR inhibitors gefitinib, erlotinib (OSI-774), lapatinib 
(GW-572016), and canertinib (CI-1033); VEGFR inhibitors semaxinib (SU5416), vatalanib 
(PTK787/ZK222584), sutent (SU11248), and sorafenib (BAY 43-9006); and PDGF inhibitor 
leflunomide (SU101) [156,162]. 
Regarding serine/threonine kinases, aurora kinase (A, B, and C) inhibitors are promising 
antineoplastic agents. Aurora kinases are implicated in the control of chromosome assembly and 
segregation during mitosis and, therefore, their abnormal expression/regulation in tumor cells is 
closely associated with genetic instability [163]. Most inhibitors target better described members 
(kinase A and B), though some, such as AZD1152 (upon conversion into its active metabolite 
AZD1152-HQPA), present high affinity for all aurora kinases (for a review see [156,163]).  
mTOR is also another target of cancer therapy due to its central position in several pro-survival 
pathways (e.g., PI3K/Akt/mTOR). In normal cells, mTOR is activated by either upstream positive 
regulators, such as growth factors, and inactivated by negative regulators, such as the phosphatase and 
tensin homolog (PTEN) [164]. Interestingly, mTOR and many of its regulating molecules present 
alterations in malignant cells, supporting the therapeutic value of mTOR inhibition. As the mammalian 
target of rapamycin, mTOR was identified as a rapamycin substrate [165], and rapamycin was the first 
inhibitor tested against different human cancer cell lines. Despite initial positive results, unfavorable 
pharmacokinetic properties required the synthesis of new analogues, such as temsirolimus (CCI-779), 
everolimus (RAD001), and ridaforolimus (AP23573 or deforolimus). All of these compounds act by 
forming a complex with FK506 binding protein-12 (FKBP-12), which is recognized by mTOR, 
resulting in the inhibition of its activity [166] (for a review see [156,164]).  
5.2.8. Others 
This group includes other novel strategies that are still in early phases, such as inhibitors of IAPs, 
LMP driving compounds, and mitochondria targeted compounds (also known as mitocans). The 
mammalian IAP family is formed by a group of eight members capable of directly inhibiting caspases 
(already mentioned in Section 3.2.1). The release of the natural IAP inhibitor (i.e., Smac/DIABLO) 
from the mitochondria allows caspase activation and, ultimately, apoptotic death of the cell. 
Baculoviral IAP repeat (BIR) domains (from 1, up to 3) are the identifying structural motifs in IAPs 
and in charge of mediating the interaction with caspases. In this regard, the current inhibitors of 
cellular IAP activity are mainly BIR2 or BIR3 antagonists (e.g., embelins, monovalent Smac mimetics, 
and arylsulfonamides; Figure 6) that are still in preclinical or early clinical phases (for a complete 
review see [167]).  
Lysosomes, hydrolase-containing acidic organelle described by de Duve et al. [168] are gaining 
importance in different processes in addition to macromolecule degradation. Lysosomes contain large 
amounts and varieties of cathepsins (cysteine, aspartate, or serine proteases), as well as sphingolipid 
lipases (acidic sphingomyelinase and ceramidase). In addition, transmembrane vacuolar H+-ATPase, 
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lysosome-associated membrane protein (LAMP) 1 and 2, and CD63 (LIMP-1/LAMP-3) are among the 
long list of proteins required for correct lysosomal function [169]. As mentioned above in Section 
3.2.4, numerous cancer treatments induce direct or indirect permeabilization of the lysosomal 
membrane, and ultimately cell death. Groth-Pedersen et al. [170] presented an updated list of established 
and putative lysosomal cell death-inducing cancer treatments. Among those directly affecting lysosomal 
stability, we can highlight lysosomotrophic compounds, such as hydroxychloroquine, BAMLET, 
siramesine, LeuLeuOMe, and sphingosine, which allow the release of cathepsins and activate apoptotic 
pathways (Figure 6).  
Mitochondrion has been an intriguing organelle in cancer, especially since Otto Warburg [171] 
postulated in 1924 that malignant tumor cells can be caused by a shift in the energy (ATP) production 
system. An increased non-oxidative breakdown of glucose (also called glycolysis) was observed in 
tumor cells compared to normal cells (known as the Warburg effect). In fact, Warburg interpreted 
these studies as the result of defective mitochondrial oxidative phosphorylation with the compensatory 
up-regulation of glycolysis [171]. Nevertheless, the increase in glycolysis-dependent energy 
production does not mean a lack of oxidative phosphorylation or resistance against MMP. In fact, 
current anticancer strategies involving mitochondria are being pursued to: a) induce direct MMP (e.g., 
by interfering with PTP components such as 3-PB, bisphosphonates, or CD437), b) induce indirect 
membrane permeabilization (e.g., through oxidative stress-driven damage), or c) inhibit the glycolytic 
breakdown of glucose (e.g., by blocking pyruvate dehydrogenase kinase) (for a review see [172,173]). 
6. Conclusions 
Knowledge regarding cell death/survival pathways and the characterization of the main altered 
pathways in cancer has allowed an exponential increase in anticancer strategies and potential 
antineoplastic drugs. Nevertheless, the success in obtaining a final anticancer treatment requires  
long-term studies and a few of the proposed compounds reaching the finishing line. Moreover, the 
huge variability observed in cancer represents an intrinsic challenge of the disease. With this adverse 
scenario in mind, movement towards an individualized characterization of the disease represents an 
inestimable advance, which is desirable for the future. The best chances for treatment seem to rely on a 
combination of the better-known broad-spectrum antitumoral drugs, together with the design of 
selective molecule-targeted compounds against altered regulatory molecules.  
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